Sartorius AG · XETR:SRT

Sartorius — Sartorius Stedim Biotech — Investor Presentation (February 2019)

25 slides from Sartorius's investor presentation, February 2019

  1. Slide 1: Company Presentation

    Company Presentation February 2019 1

  2. Slide 2: Agenda

    Agenda 01 Sartorius Stedim Biotech in Brief 02 Total Solutions Provider for the Biopharma Industry 03 Sartorius Stedim Biotech 2020 and 2025

  3. Slide 3: Sartorius Stedim Biotech in 2018

    Sartorius Stedim Biotech in 2018 Internationally leading Bioprocess Technologies Provider > €1.21 bn ~€177 mn ~ 35% ~ 42% ~ 23% Sales revenue Investments Americas EMEA Asia | Pacific ~ €342 mn 28.2% Earnings1 Earnings1 margin ~ €8.1 bn Sales revenue by region Market capitalization2 Publicly listed s

  4. Slide 4: Global player with over 30 sales and production sites

    Global player with over 30 sales and production sites Americas Asia|Pacific USA: Massachusetts | India | Singapore | Vietnam | New York, North Carolina, China | Malaysia | South Pennsylvania, Colorado | Korea | Japan | Australia Puerto Rico | Mexico | EMEA Brazil | Argentina Belgium | Ireland | UK |

  5. Slide 5: Around 5,600 employees worldwide

    Around 5,600 employees worldwide ~ +70% 2018 2013 ~ 880 ~4,000 ~750 Americas EMEA Asia|Pacific Employees by Regions Employees growth 2012-2018 Figures as of Dec. 31, 2018 5

  6. Slide 6: Our corporate values

    “EE sartorius stedim biotech Our corporate values SUSTAINABILITY Growing profitably and taking responsibility for all stakeholders OPENNESS Driving change internally and externally ENJOYMENT Working in an energetic and rewarding environment

  7. Slide 7: Agenda

    Agenda 01 Sartorius Stedim Biotech in Brief 02 Total Solutions Provider for the Biopharma Industry 03 Sartorius Stedim Biotech 2020 and 2025

  8. Slide 8: Unique position in an attractive market

    Unique position in an attractive market  Solution provider for biomanufacturing  Highly regulated environment | validated processes  Broadest portfolio in the industry 8

  9. Slide 9: What are biopharmaceuticals?

    What are biopharmaceuticals? Living, genetically modified Cells Production Injection | Infusion Advantages Challenges  First-time or improved treatment of serious illnesses,  R&D and production labor-intensive such as cancer, multiple sclerosis, rheumatism  High therapy costs: biologics ~ $50 vs.

  10. Slide 10: Focusing on Biopharma for more than 15 years

    Focusing on Biopharma for more than 15 years Bioprocess Solutions Division Cell line and Production Molecule development process development upstream & downstream Quality & testing Lab Products & Services Division 10

  11. Slide 11: Driven by strong fundamentals, Biopharma is a growth market

    Driven by strong fundamentals, Biopharma is a growth market Favorable demographics Increasing healthcare spending 9 bn +6.4% people by 2050 CAGR of which >2 bn of worldwide 60yrs or older prescription drug sales 2018-2024 ~8% CAGR of biopharma market 2018-2025 Favorable R&D pipeline; strong Rise of

  12. Slide 12: Well positioned as a Total solution provider across the Biopharma process chain

    Well positioned as a Total solution provider across the Biopharma process chain Process Development Production Cell Culture Media Fermentation Cell Harvesting Buffer | Preparation Purification Services 12

  13. Slide 13: Pioneer in single-use manufacturing technologies

    Pioneer in single-use manufacturing technologies Past Present High initial cost + CAPEX reduction over entire lifecycle Considerable cleaning effort + Lower water and energy consumption Risk of cross-contamination + Higher flexibility 13

  14. Slide 14: Around 75% of recurrent business with single-use products

    Around 75% of recurrent business with single-use products Equipment ~ 25 % Single-use ~ €1,21 bn ~ 75 % Figures as of Dec. 31, 2018 14

  15. Slide 15: Leading market positions worldwide

    Leading market positions worldwide Filtration TOP 3 Fluid Management #1 Fermentation #1  > 85% of sales revenue generated from top 1-3 positions 15

  16. Slide 16: Agenda

    Agenda 01 Sartorius Stedim Biotech in Brief 02 Total Solutions Provider for the Biopharma Industry 03 Sartorius Stedim Biotech 2020 and 2025

  17. Slide 17: On track to deliver on our 2020 goals that were set in 2011

    On track to deliver on our 2020 goals that were set in 2011 ~€2.8 bn 2200 50 49 48 2000 47 46 45 44 1800 43 ~+7-11% ~€1.5 bn 42 41 1600 +13.7% 40 39 38 1400 +4.1% 37 +20.4% €1.2 bn 36 35 +19.4% 1200 34 33 1000 +15.9% 32 31 +10.8% 30 29 +10.3% ~29-30 ~30 28 +~1pp 800 28.2 27 27.5 27.3 26 26.2 25 600

  18. Slide 18: Portfolio continuously enhanced via strategic acquisitions

    Portfolio continuously enhanced via strategic acquisitions Process Development Production Small-scale single-use bioreactors Q4 2013 Cell culture media Q1 2013 Single-use technology for sampling Cell line development Q2 2014 services Q3 2015 Single-use Software for bioprocess centrifuges Testing in

  19. Slide 19: Infrastructure prepared for further growth

    Infrastructure prepared for further growth Yauco, Puerto Rico: Doubling of fluid Aubagne, France: Capacity extension of management and filter capacities bag production ~15% Capex ratio Goettingen, Germany: Extension New ERP and extension of global IT infrastructure 19

  20. Slide 20: Our Growth Targets Up to 2025

    Our Growth Targets Up to 2025 Strategic Initiatives 2025 Targets Regional  Participate in strong Chinese market growth  Continue to outgrow the important U.S. market ~€2.8 bn Portfolio Sales revenue  Adding high-impact innovation, e.g. digital tools  Enhance process development capabilities  Ex

  21. Slide 21: Thank you very much for your attention

    Thank you very much for your attention

  22. Slide 22: Disclaimer

    Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materia

  23. Slide 23: Scalable products from process development to production

    Scalable products from process development to production Fermentation | Cell culture ambr® UniVessel® SU BIOSTAT® RM BIOSTAT STR® 15 up to 250 ml 0.6 up to 2 liters 0.1 up to 300 liters 12.5 up to 2,000 liters 23

  24. Slide 24: Scalable products from process development to production

    Scalable products from process development to production Sartobind® membrane adsobers (Purification) pico nano mini 5“ 10“ 20“ 30“ Jumbo 24

  25. Slide 25: Scalable products from process development to production

    Scalable products from process development to production Fluid Management Flexsafe® & Celsius®-Pak Flexsafe® & Flexel® Flexsafe ® & Flexel® Flexboy® Bags for Mixer 50 milliliters 30 milliliters 100 up to 3,000 liters 50 up to 3,000 liters up to 50 liters up to 16.6 liters 25

Sartorius Stedim Biotech — Investor Presentation (February 2019) on 6ix